期刊文献+

非小细胞肺癌患者血清胸苷激酶1浓度与临床分期及病理类型的相关性 被引量:5

Association of serum thymidine kinase 1 and clinical stages and pathological types in patients with nonsmall cell lung cancer
原文传递
导出
摘要 目的探讨血清胸苷激酶1(TK1)与非小细胞肺癌(NSCLC)临床分期及病理类型的关系。方法采用免疫印迹增强化学发光法检测49例NSCLC患者血清TK1的浓度。其中,腺癌33例,鳞癌16例。结果鳞癌患者血清TK1浓度高于腺癌患者[(3.63±1.15)pmol/L vs.(2.58±1.01)pmol/L](P<0.05)。临床分期Ⅲ+Ⅳ期NSCLC患者血清TK1浓度高于Ⅰ+Ⅱ期患者(P<0.05)。血清TK1浓度与是否有淋巴结转移及肿瘤分化程度之间无明显相关性(P>0.05)。结论术前检测NSCLC患者血清TK1浓度对判断肿瘤临床分期及病理类型有重要的临床意义。 Objective To analyze the relationship between serum thymidine kinase 1(TK1)and tumor stages and pathological types in the patients with non-small cell lung cancer(NSCLC).Methods Serum TK1 was determined by enhanced chemiluminescence assay(ECLA)in 49 patients with NSCLC,of whom 16 cases were with squamous cell lung cancer(group A)and 33 cases were with lung adenocarcinoma(group B).Results Serum TK1 was higher in group A than that in group B[(3.63±1.15)pmol/L vs.(2.58±1.01)pmol/L](P〈0.05).Serum levels of TK1 were significantly higher in the patients with stagesⅢ+Ⅳ of NSCLC than those with stagesⅠ+Ⅱ(P〈0.05).Serum levels of TK1 were not significantly correlated to lymph node metastasis or tumor differentiation(P〉0.05).Conclusion Detection of serum TK1 before operation has an important clinical significance in evaluating the tumor clinical stages and pathological types in the patients with NSCLC.
出处 《江苏医药》 CAS 北大核心 2014年第21期2555-2557,共3页 Jiangsu Medical Journal
关键词 胸苷激酶1 非小细胞肺癌 Thymidine kinase 1 Non-small cell lung cancer
  • 引文网络
  • 相关文献

参考文献6

  • 1O′Neill KL,Buckwalter MR,Murray BK.Thymidine kinase:diagnostic and prognostic potential[J].Expert Rev Mol Diagn,2001,1(4):428-433.
  • 2Ke PY,Chang ZF.Mitotic degradation of human thymidine kinase 1is dependent on the anaphase-promoting complex/cyclosome-cdh1-mediated pathway[J].Mol Cell Biol,2004,24(2):514-526.
  • 3Brockenbrough JS,Rasey JS,Grierson JR,et al.A simple quantitative assay for the activity of thymidine kinase 1in solid tumors[J].Nucl Med Biol,2007,34(6):619-623.
  • 4Muley T,Fetz TH,Dienemann H,et al.Tumor volume and tumor marker index based on CYFRA 21-1and CEA are strong prognotic factors in operated early stage NSCLC[J].Lung Cancer,2008,60(3):408-415.
  • 5唐兴,马海涛,王利瑞.血清胸苷激酶1与CEA、CA125、CA72-4、CYFRA211、NSE联合检测在肺癌诊断中的价值[J].江苏医药,2012,38(5):545-547. 被引量:3
  • 6He Q,Zhang PG,Zou L,et al.Concentration of thymidine kinase 1in serum(S-TK1)is a more sensitive proliferation maker in human solid tumor than its activity[J].Oncology Report,2005,14(4):1013-1019.

二级参考文献12

  • 1O′Neill KL,Buckwalter MR,Murray BK.Thymidine kinase:diagnostic and prognostic potential[J].Expert Rev MolDiagn,2001,1(4):428-433.
  • 2Ke PY,Chang ZF.Mitotic degradation of human thymidinekinase 1is dependent on the anaphase-promoting complex/cyclosome-cdh1-mediated pathway[J].Mol Cell Biol,2004,24(2):514-526.
  • 3Li HX,Lei DS,Wang XQ,et al.Serum thymidine kinase 1isaprognostic and monitoring factor in patients with non-smallcell lung cancer[J].Oncol Rep,2005,13(1):145-149.
  • 4Alatas F,Alatas O,Metintas M.Diagnostic value of CEA,CA153,CA199,CYFRA21-1,NSE and TSA,assay in pleuraleffusions[J].Lungcancer,2001,31(1):9.
  • 5Domenico F,Gianfraneo B,Cristina G.Neuron-specific enolaseis an effective tumor marker in non-small cell lung cancer[J].Lung Cancer,2003,41(3):311.
  • 6Barlesi F,Gimenez C,Torre JP,et al.Prognostic value ofcombination of Cyfra21-1,CEA and NSE in patients withadvanced non-small cell lung cancer[J].Respiratory Medi-cine,2004,98(4):357.
  • 7Nonaka M,Kataoka D,Yamamoto S,et al.Pre-and post-op-erative serum careinoembryonic antigen in primary lung ade-nocarcinoma[J].Ann Thorac Cardiovasc Surg,2004,10(5):281-284.
  • 8叶江枫,解立新,陈勇,杜永红.血清肿瘤标志物与肺癌的关系[J].临床肺科杂志,2008,13(7):832-834. 被引量:18
  • 9王海燕,朱正学,肖燕,马楠,李红梅,文仲光.非小细胞肺癌血清中CA125、CEA的浓度及意义[J].中国肺癌杂志,2008,11(1):97-100. 被引量:36
  • 10席菁乐,郑航,罗荣城.TPS、CYFRA21-1和CEA联合检测对非小细胞肺癌的诊断价值[J].南方医科大学学报,2008,28(12):2299-2300. 被引量:11

共引文献2

同被引文献30

二级引证文献31

;
使用帮助 返回顶部